Oracle introduced Oracle Life Sciences AI Agents on Nov. 18, 2026, to assist organizations with clinical trial coordination and operational intelligence. The new tools, available to early adopters, monitor study performance and recommend actions across development workflows while maintaining human oversight.
Oracle announced the launch of Oracle Life Sciences AI Agents for clinical trial operations, available to early adopters on Nov. 18, 2026. The release contains no quantified revenue, contract, guidance or adoption figures, so it does not change the financial outlook; any market effect is limited to a modest product-announcement sentiment read.
- • Launch of Oracle Life Sciences AI Agents available for early adopters as of Nov. 18, 2026
- • Planned enhancements extending AI capabilities into clinical data management, trial design, post-trial analytics and post-market workflows
- • No revenue, pricing, contract or adoption figures disclosed in the announcement
- • Product operates with human oversight and is at the early-adopter stage, so commercial impact is unproven